Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study).

Item

http://www.wikidata.org/entity/Q36752284

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Residual edema evaluation with ...... ic macular edema (REEF study).

@en

type

Item

label

Residual edema evaluation with ...... ic macular edema (REEF study).

@en

prefLabel

Residual edema evaluation with ...... ic macular edema (REEF study).

@en

P1476

Residual edema evaluation with ...... ic macular edema (REEF study).

@en

P2093

A A Castellarin

http://www.w3.org/2001/XMLSchema#string

D J Pieramici

http://www.w3.org/2001/XMLSchema#string

D S Dhoot

http://www.w3.org/2001/XMLSchema#string

M Bennett

http://www.w3.org/2001/XMLSchema#string

M Nasir

http://www.w3.org/2001/XMLSchema#string

M Rabena

http://www.w3.org/2001/XMLSchema#string

N Steinle

http://www.w3.org/2001/XMLSchema#string

R F See

http://www.w3.org/2001/XMLSchema#string

R L Avery

http://www.w3.org/2001/XMLSchema#string

S Couvillion

http://www.w3.org/2001/XMLSchema#string

P2860

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.

Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

P2888

eye.2014.338

P304

534-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.2014.338

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25633882

http://www.w3.org/2001/XMLSchema#string

P932

4816366

http://www.w3.org/2001/XMLSchema#string